A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients With Unresectable Stage III and IV Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 21 Dec 2018
At a glance
- Drugs Denosumab (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms CHARLI
- 31 Aug 2018 Biomarkers information updated
- 14 Dec 2017 Planned End Date changed from 1 Dec 2022 to 1 Jun 2023.
- 14 Dec 2017 Planned primary completion date changed from 1 Dec 2019 to 1 Jun 2021.